Medical marijuana company Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX:KHRNF) (Frankfurt: A2JMZC) is opening another Zerenia location in Peru in partnership with the renowned pain clinic, CDL.
Khiron In Peru Highlights
- This addition collectively brings the company's total clinic count to 16 globally, which includes presence in Colombia, Peru and the United Kingdom
- Peru represented 5% of the total Latin America unit sales in 2021
- In the second half of 2021, the company opened its first Zerenia clinic in Lima, in partnership with Clínica Montesur. Since opening the clinic, over 80% of the consults resulted in cannabis prescriptions
- In August 2021, Khiron obtained registration of its first two medical cannabis products in Peru, available for sale nationwide in late Q4 2021
The Partnership With CDL
As a specialized pain clinic, CDL already has pain management specialists and a patient base exclusively related to chronic and acute pain. Starting February 2022, Khiron will be leveraging the CDL's existing infrastructure and reputation to provide access to cannabinoid-based treatments to a growing group of patients in Lima and surrounding areas.
Alvaro Torres, Khiron CEO and director, commented, "In 2021, Peru represented around 5% of our total volume sales in Latin America, and now with our new partnership with CDL we believe we can increase our sales cost-effectively by expanding Zerenia in Peru. In our first clinic in Peru, over 80% of total consultations resulted in medical cannabis prescriptions, further validating our unique, evidence and service-driven strategy. By establishing a new pain-focused partnership with CDL in Lima, we plan to grow beyond our current capacity and offer different treatment alternatives to more than 10,000 patients annually."
Price Action
Khiron shares closed Wednesday trading session 3.00% lower at $0.17 per share.
Photo: Courtesy of CNW Group/Khiron Life Sciences Corp.
